September 20, 2013
Eisai announced on September 18 that its US research subsidiary H3 Biomedicine Inc. has entered into a collaborative agreement with Polish drug discovery company Selvita S.A. to develop novel anticancer agents. Under the agreement, the two companies will conduct joint...read more